Effects of a New Emollient-Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis
Background/Objectives The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical...
Saved in:
Published in | Pediatric dermatology Vol. 33; no. 2; pp. 165 - 171 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.03.2016
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background/Objectives
The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.
Methods
Fifty‐four children (1–4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.
Results
We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier‐specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H′ = 2.3) did not vary with treatment in either group.
Conclusion
Twice‐daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity. |
---|---|
AbstractList | The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.
Fifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.
We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group.
Twice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity. Background/Objectives The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD. Methods Fifty‐four children (1–4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days. Results We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier‐specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H′ = 2.3) did not vary with treatment in either group. Conclusion Twice‐daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity. The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.BACKGROUND/OBJECTIVESThe use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.Fifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.METHODSFifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.We found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group.RESULTSWe found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group.Twice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.CONCLUSIONTwice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity. |
Author | Schmitt, Anne-Marie Redoulès, Daniel Villeneuve, Cecile Bacquey, Adeline Bianchi, Pascale Phulpin, Chloe Theunis, Jennifer Patrizi, Annalisa Casas, Christiane Mengeaud, Valerie |
AuthorAffiliation | 2 Department of Dermatology University of Bologna Bologna Italy 1 European Center for Skin Research Pierre Fabre Dermo‐Cosmétique Toulouse France |
AuthorAffiliation_xml | – name: 1 European Center for Skin Research Pierre Fabre Dermo‐Cosmétique Toulouse France – name: 2 Department of Dermatology University of Bologna Bologna Italy |
Author_xml | – sequence: 1 givenname: Pascale surname: Bianchi fullname: Bianchi, Pascale organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 2 givenname: Jennifer surname: Theunis fullname: Theunis, Jennifer email: jennifer.theunis@pierre-fabre.com organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 3 givenname: Christiane surname: Casas fullname: Casas, Christiane organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 4 givenname: Cecile surname: Villeneuve fullname: Villeneuve, Cecile organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 5 givenname: Annalisa surname: Patrizi fullname: Patrizi, Annalisa organization: Department of Dermatology, University of Bologna, Bologna, Italy – sequence: 6 givenname: Chloe surname: Phulpin fullname: Phulpin, Chloe organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 7 givenname: Adeline surname: Bacquey fullname: Bacquey, Adeline organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 8 givenname: Daniel surname: Redoulès fullname: Redoulès, Daniel organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 9 givenname: Valerie surname: Mengeaud fullname: Mengeaud, Valerie organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France – sequence: 10 givenname: Anne-Marie surname: Schmitt fullname: Schmitt, Anne-Marie organization: European Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27001317$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU9vEzEQxS1URNPCgS-AfITDtvb-sTcXpDZNU1BbkAhwtLz2LDH12sF2CL32k-OSpAIEvtjW_N4bzZsDtOe8A4SeU3JE8zleajiiJW_ZIzSiTdkUtOZkD40Ir1jRkprto4MYvxJCWsboE7RfckJoRfkI3U37HlSK2PdY4mtY4-ngrTXgUnEqI2g8DyDTkP_YO_zhxjh8ZVTwvfVB4lNppVOApdP5HYKBgM9XTiWT4YxOFsbqAA6vTVpkodX4JPmlUfgMwiCTSSY-RY97aSM8296H6OP5dD65KC7fzd5MTi4LVTd5jo41taZ1LTVrupr1FRu3mpRcMVJxMs6DkZJWHaOtUiUQrrq21wp4Oe6prru-OkSvN77LVTdALrkUpBXLYAYZboWXRvxZcWYhvvjvoiGc8pJlg5dbg-C_rSAmMZiowOYIwK-ioJw3VUsprzP64vdeD012wWfgeAPkKGMM0AtlkryPLbc2VlAi7lcr8mrFr9Vmxau_FDvTf7Fb97WxcPt_ULw_m-4UxUZhYoIfDwoZbgTjFW_E5-uZmNC3M_ppciXm1U8MSsLA |
CitedBy_id | crossref_primary_10_1080_09546634_2017_1328938 crossref_primary_10_1016_j_aller_2018_06_008 crossref_primary_10_1097_DER_0000000000000589 crossref_primary_10_1007_s13555_022_00685_2 crossref_primary_10_25259_IJDVL_1384_20 crossref_primary_10_1111_jdv_18947 crossref_primary_10_1080_09546634_2018_1516030 crossref_primary_10_15690_vsp_v19i4S_2144 crossref_primary_10_1111_jdv_18949 crossref_primary_10_15690_vsp_v21i5_2449 crossref_primary_10_1016_S0151_9638_17_31042_6 crossref_primary_10_1111_exd_13336 crossref_primary_10_15690_pf_v16i2_2006 crossref_primary_10_3389_fphys_2024_1322205 crossref_primary_10_1055_a_2104_2848 crossref_primary_10_1080_09546634_2019_1708246 crossref_primary_10_1002_14651858_CD012119_pub2 crossref_primary_10_3390_jcm11174974 crossref_primary_10_1016_j_micpath_2024_107163 crossref_primary_10_15690_pf_v16i5_2060 crossref_primary_10_1007_s40257_020_00551_x crossref_primary_10_15690_vsp_v19i6_2144 crossref_primary_10_1111_jdv_14891 crossref_primary_10_1111_jdv_19125 crossref_primary_10_1080_13543784_2018_1494723 crossref_primary_10_3390_cosmetics9040075 crossref_primary_10_1111_bjd_15390 crossref_primary_10_1155_2023_2375223 crossref_primary_10_1111_exd_14435 crossref_primary_10_1007_s13671_024_00453_9 crossref_primary_10_1515_sjdv_2016_0012 crossref_primary_10_15690_vsp_v20i5_2309 crossref_primary_10_1007_s40257_020_00529_9 crossref_primary_10_1080_17843286_2023_2285576 crossref_primary_10_1007_s13555_020_00415_6 crossref_primary_10_3390_jcm13082185 crossref_primary_10_1007_s13555_024_01119_x crossref_primary_10_1016_j_anai_2017_09_061 crossref_primary_10_34883_PI_2020_23_1_013 crossref_primary_10_3390_jcm13030863 crossref_primary_10_1007_s13555_018_0243_4 crossref_primary_10_1111_jdv_16083 |
Cites_doi | 10.1016/j.jaci.2007.12.1161 10.1016/j.jaci.2014.08.008 10.4168/aair.2014.6.4.276 10.1111/j.1365-2133.2007.08112.x 10.1159/000245677 10.1111/j.1468-3083.2012.04635.x 10.1016/j.jaci.2012.12.672 10.1186/1471-2180-10-206 10.1016/j.jaci.2007.08.067 10.1159/000247298 10.5021/ad.2012.24.4.413 10.1128/IAI.01304-08 10.1046/j.1365-2222.2000.00848.x 10.1101/gr.131029.111 10.1159/000143391 10.1111/j.1468-3083.2009.03415.x 10.1111/j.1600-0625.2011.01417.x 10.1016/j.clindermatol.2011.08.015 10.1016/j.jaci.2013.07.008 10.1038/jid.2011.306 10.2165/00128071-200809010-00005 10.1038/jid.2009.133 |
ContentType | Journal Article |
Copyright | 2016 Pierre Fabre Dermo‐Cosmétique. published by Wiley Periodicals, Inc. 2016 Pierre Fabre Dermo-Cosmétique. Pediatric Dermatology published by Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2016 Pierre Fabre Dermo‐Cosmétique. published by Wiley Periodicals, Inc. – notice: 2016 Pierre Fabre Dermo-Cosmétique. Pediatric Dermatology published by Wiley Periodicals, Inc. |
DBID | BSCLL 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1111/pde.12786 |
DatabaseName | Istex Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Bianchi et al |
EISSN | 1525-1470 |
EndPage | 171 |
ExternalDocumentID | PMC5071726 27001317 10_1111_pde_12786 PDE12786 ark_67375_WNG_C1JG1VCM_T |
Genre | article Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Pierre Fabre Dermo‐Cosmétique |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1OB 1OC 29O 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPPZ ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZGI ZXP ZZTAW ~IA ~WT 24P AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY 5PM |
ID | FETCH-LOGICAL-c4536-b654d144ad65b46f3698d027c6037096610213b618cc2e07cb8fdce729f1d4bf3 |
IEDL.DBID | DR2 |
ISSN | 0736-8046 1525-1470 |
IngestDate | Thu Aug 21 14:20:22 EDT 2025 Fri Jul 11 07:55:26 EDT 2025 Wed Feb 19 01:55:55 EST 2025 Tue Jul 01 01:46:15 EDT 2025 Thu Apr 24 23:01:20 EDT 2025 Wed Jan 22 16:32:40 EST 2025 Wed Oct 30 09:50:58 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Attribution-NonCommercial http://creativecommons.org/licenses/by-nc/4.0 2016 Pierre Fabre Dermo-Cosmétique. Pediatric Dermatology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4536-b654d144ad65b46f3698d027c6037096610213b618cc2e07cb8fdce729f1d4bf3 |
Notes | Pierre Fabre Dermo-Cosmétique ArticleID:PDE12786 istex:1AE044DD90E23D377EC85C492421648E00A02626 ark:/67375/WNG-C1JG1VCM-T ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 These authors contributed equally to this work. |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpde.12786 |
PMID | 27001317 |
PQID | 1775381174 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5071726 proquest_miscellaneous_1775381174 pubmed_primary_27001317 crossref_citationtrail_10_1111_pde_12786 crossref_primary_10_1111_pde_12786 wiley_primary_10_1111_pde_12786_PDE12786 istex_primary_ark_67375_WNG_C1JG1VCM_T |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March/April 2016 |
PublicationDateYYYYMMDD | 2016-03-01 |
PublicationDate_xml | – month: 03 year: 2016 text: March/April 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Pediatric dermatology |
PublicationTitleAlternate | Pediatr Dermatol |
PublicationYear | 2016 |
Publisher | Blackwell Publishing Ltd John Wiley and Sons Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley and Sons Inc |
References | Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-1908. Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850-859. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19. Grzanka A, Zebracka-Gala J, Rachowska R et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012;21:184-188. Gupta J, Grube E, Ericksen MB et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725-730. e722 Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-779. Wu GD, Lewis JD, Hoffmann C et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16s sequence tags. BMC Microbiol 2010;10:206. Oranje AP, Glazenburg EJ, Wolkerstorfer A et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-648. Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013;131:295-299. e1-e27 Darsow U, Wollenberg A, Simon D et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-328. Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014;6:276-287. Hon KL, Wong KY, Leung TF et al. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008;9:45-50. Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012;30:286-296. Schmitt J, Langan S, Deckert S et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013;132:1337-1347. Baurecht H, Irvine AD, Novak N et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:1406-1412. Clarke SR, Andre G, Walsh EJ et al. Iron-regulated surface determinant protein a mediates adhesion of Staphylococcus aureus to human corneocyte envelope proteins. Infect Immun 2009;77:2408-2416. Stalder JF, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31. Na SY, Roh JY, Kim JM et al. Analysis of colonization and genotyping of the exotoxins of Staphylococcus aureus in patients with atopic dermatitis. Ann Dermatol 2012;24:413-419. Bianchi P, Ribet V, Casas C et al. Analysis of gene expression in atopic dermatitis using a microabrasive method. J Invest Dermatol 2012;132:469-472. Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000;30:994-1000. Casas C, Ginisty H, Alvarez-Georges S et al. Molecular characterization of inflammation and Staphylococcus aureus colonization of involved skin of atopic dermatitis patients. A non-invasive approach. Skin Pharmacol Physiol 2008;21:260-268. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060. 2009; 77 2010; 10 2007; 157 2012; 132 2010; 24 1997; 195 2000; 30 2007; 120 2008; 9 2008; 21 2013; 132 2012; 26 2013; 131 2009; 129 2012; 24 2008; 121 2012; 22 2014; 6 2012; 21 1993; 186 2014; 134 2012; 30 e_1_2_6_21_1 e_1_2_6_10_1 e_1_2_6_20_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_19_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_3_1 e_1_2_6_11_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_12_1 e_1_2_6_22_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1 24035157 - J Allergy Clin Immunol. 2013 Dec;132(6):1337-47 9267730 - Dermatology. 1997;195(1):10-9 17714568 - Br J Dermatol. 2007 Oct;157(4):645-8 21956121 - J Invest Dermatol. 2012 Feb;132(2):469-72 10848922 - Clin Exp Allergy. 2000 Jul;30(7):994-1000 20673359 - BMC Microbiol. 2010 Jul 30;10:206 19494826 - J Invest Dermatol. 2009 Aug;129(8):1892-908 22310478 - Genome Res. 2012 May;22(5):850-9 18249438 - J Allergy Clin Immunol. 2008 Mar;121(3):725-730.e2 19732254 - J Eur Acad Dermatol Venereol. 2010 Mar;24(3):317-28 17980411 - J Allergy Clin Immunol. 2007 Dec;120(6):1406-12 18092843 - Am J Clin Dermatol. 2008;9(1):45-50 23197906 - Ann Dermatol. 2012 Nov;24(4):413-9 18612217 - Skin Pharmacol Physiol. 2008;21(5):260-8 22142393 - Exp Dermatol. 2012 Mar;21(3):184-8 25282559 - J Allergy Clin Immunol. 2014 Oct;134(4):769-79 19307218 - Infect Immun. 2009 Jun;77(6):2408-16 22805051 - J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60 24991450 - Allergy Asthma Immunol Res. 2014 Jul;6(4):276-87 23374261 - J Allergy Clin Immunol. 2013 Feb;131(2):295-9.e1-27 8435513 - Dermatology. 1993;186(1):23-31 22507043 - Clin Dermatol. 2012 May-Jun;30(3):286-96 |
References_xml | – reference: Casas C, Ginisty H, Alvarez-Georges S et al. Molecular characterization of inflammation and Staphylococcus aureus colonization of involved skin of atopic dermatitis patients. A non-invasive approach. Skin Pharmacol Physiol 2008;21:260-268. – reference: Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012;30:286-296. – reference: Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000;30:994-1000. – reference: Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-1908. – reference: Bianchi P, Ribet V, Casas C et al. Analysis of gene expression in atopic dermatitis using a microabrasive method. J Invest Dermatol 2012;132:469-472. – reference: Wu GD, Lewis JD, Hoffmann C et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16s sequence tags. BMC Microbiol 2010;10:206. – reference: Schmitt J, Langan S, Deckert S et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013;132:1337-1347. – reference: Baurecht H, Irvine AD, Novak N et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:1406-1412. – reference: Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060. – reference: Na SY, Roh JY, Kim JM et al. Analysis of colonization and genotyping of the exotoxins of Staphylococcus aureus in patients with atopic dermatitis. Ann Dermatol 2012;24:413-419. – reference: Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-779. – reference: Grzanka A, Zebracka-Gala J, Rachowska R et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012;21:184-188. – reference: Stalder JF, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31. – reference: Clarke SR, Andre G, Walsh EJ et al. Iron-regulated surface determinant protein a mediates adhesion of Staphylococcus aureus to human corneocyte envelope proteins. Infect Immun 2009;77:2408-2416. – reference: Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014;6:276-287. – reference: Hon KL, Wong KY, Leung TF et al. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008;9:45-50. – reference: Darsow U, Wollenberg A, Simon D et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-328. – reference: Gupta J, Grube E, Ericksen MB et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725-730. e722 – reference: Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850-859. – reference: Schneider L, Tilles S, Lio P et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013;131:295-299. e1-e27 – reference: Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19. – reference: Oranje AP, Glazenburg EJ, Wolkerstorfer A et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-648. – volume: 131 start-page: 295 year: 2013 end-page: 299 article-title: Atopic dermatitis: a practice parameter update 2012 publication-title: J Allergy Clin Immunol – volume: 30 start-page: 286 year: 2012 end-page: 296 article-title: Effect of moisturizers on epidermal barrier function publication-title: Clin Dermatol – volume: 132 start-page: 469 year: 2012 end-page: 472 article-title: Analysis of gene expression in atopic dermatitis using a microabrasive method publication-title: J Invest Dermatol – volume: 121 start-page: 725 year: 2008 end-page: 730 article-title: Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity publication-title: J Allergy Clin Immunol – volume: 24 start-page: 413 year: 2012 end-page: 419 article-title: Analysis of colonization and genotyping of the exotoxins of in patients with atopic dermatitis publication-title: Ann Dermatol – volume: 26 start-page: 1045 year: 2012 end-page: 1060 article-title: Guidelines for treatment of atopic eczema (atopic dermatitis) part I publication-title: J Eur Acad Dermatol Venereol – volume: 10 start-page: 206 year: 2010 article-title: Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16s sequence tags publication-title: BMC Microbiol – volume: 186 start-page: 23 year: 1993 end-page: 31 article-title: Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis publication-title: Dermatology – volume: 129 start-page: 1892 year: 2009 end-page: 1908 article-title: Epidermal barrier dysfunction in atopic dermatitis publication-title: J Invest Dermatol – volume: 120 start-page: 1406 year: 2007 end-page: 1412 article-title: Toward a major risk factor for atopic eczema: meta‐analysis of filaggrin polymorphism data publication-title: J Allergy Clin Immunol – volume: 9 start-page: 45 year: 2008 end-page: 50 article-title: Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis publication-title: Am J Clin Dermatol – volume: 30 start-page: 994 year: 2000 end-page: 1000 article-title: Colonization with superantigen‐producing is associated with increased severity of atopic dermatitis publication-title: Clin Exp Allergy – volume: 134 start-page: 769 year: 2014 end-page: 779 article-title: Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches publication-title: J Allergy Clin Immunol – volume: 24 start-page: 317 year: 2010 end-page: 328 article-title: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis publication-title: J Eur Acad Dermatol Venereol – volume: 157 start-page: 645 year: 2007 end-page: 648 article-title: Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three‐item severity score publication-title: Br J Dermatol – volume: 21 start-page: 260 year: 2008 end-page: 268 article-title: Molecular characterization of inflammation and colonization of involved skin of atopic dermatitis patients. A non‐invasive approach publication-title: Skin Pharmacol Physiol – volume: 6 start-page: 276 year: 2014 end-page: 287 article-title: Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis publication-title: Allergy Asthma Immunol Res – volume: 132 start-page: 1337 year: 2013 end-page: 1347 article-title: Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation publication-title: J Allergy Clin Immunol – volume: 21 start-page: 184 year: 2012 end-page: 188 article-title: The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions publication-title: Exp Dermatol – volume: 77 start-page: 2408 year: 2009 end-page: 2416 article-title: Iron‐regulated surface determinant protein a mediates adhesion of to human corneocyte envelope proteins publication-title: Infect Immun – volume: 195 start-page: 10 year: 1997 end-page: 19 article-title: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis publication-title: Dermatology – volume: 22 start-page: 850 year: 2012 end-page: 859 article-title: Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis publication-title: Genome Res – ident: e_1_2_6_19_1 doi: 10.1016/j.jaci.2007.12.1161 – ident: e_1_2_6_3_1 doi: 10.1016/j.jaci.2014.08.008 – ident: e_1_2_6_10_1 doi: 10.4168/aair.2014.6.4.276 – ident: e_1_2_6_16_1 doi: 10.1111/j.1365-2133.2007.08112.x – ident: e_1_2_6_12_1 doi: 10.1159/000245677 – ident: e_1_2_6_7_1 doi: 10.1111/j.1468-3083.2012.04635.x – ident: e_1_2_6_8_1 doi: 10.1016/j.jaci.2012.12.672 – ident: e_1_2_6_15_1 doi: 10.1186/1471-2180-10-206 – ident: e_1_2_6_21_1 doi: 10.1016/j.jaci.2007.08.067 – ident: e_1_2_6_11_1 doi: 10.1159/000247298 – ident: e_1_2_6_17_1 doi: 10.5021/ad.2012.24.4.413 – ident: e_1_2_6_22_1 doi: 10.1128/IAI.01304-08 – ident: e_1_2_6_5_1 doi: 10.1046/j.1365-2222.2000.00848.x – ident: e_1_2_6_4_1 doi: 10.1101/gr.131029.111 – ident: e_1_2_6_6_1 doi: 10.1159/000143391 – ident: e_1_2_6_9_1 doi: 10.1111/j.1468-3083.2009.03415.x – ident: e_1_2_6_20_1 doi: 10.1111/j.1600-0625.2011.01417.x – ident: e_1_2_6_23_1 doi: 10.1016/j.clindermatol.2011.08.015 – ident: e_1_2_6_13_1 doi: 10.1016/j.jaci.2013.07.008 – ident: e_1_2_6_14_1 doi: 10.1038/jid.2011.306 – ident: e_1_2_6_18_1 doi: 10.2165/00128071-200809010-00005 – ident: e_1_2_6_2_1 doi: 10.1038/jid.2009.133 – reference: 18612217 - Skin Pharmacol Physiol. 2008;21(5):260-8 – reference: 19732254 - J Eur Acad Dermatol Venereol. 2010 Mar;24(3):317-28 – reference: 25282559 - J Allergy Clin Immunol. 2014 Oct;134(4):769-79 – reference: 17714568 - Br J Dermatol. 2007 Oct;157(4):645-8 – reference: 17980411 - J Allergy Clin Immunol. 2007 Dec;120(6):1406-12 – reference: 21956121 - J Invest Dermatol. 2012 Feb;132(2):469-72 – reference: 8435513 - Dermatology. 1993;186(1):23-31 – reference: 19494826 - J Invest Dermatol. 2009 Aug;129(8):1892-908 – reference: 22142393 - Exp Dermatol. 2012 Mar;21(3):184-8 – reference: 22507043 - Clin Dermatol. 2012 May-Jun;30(3):286-96 – reference: 9267730 - Dermatology. 1997;195(1):10-9 – reference: 18092843 - Am J Clin Dermatol. 2008;9(1):45-50 – reference: 23374261 - J Allergy Clin Immunol. 2013 Feb;131(2):295-9.e1-27 – reference: 18249438 - J Allergy Clin Immunol. 2008 Mar;121(3):725-730.e2 – reference: 19307218 - Infect Immun. 2009 Jun;77(6):2408-16 – reference: 22310478 - Genome Res. 2012 May;22(5):850-9 – reference: 22805051 - J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60 – reference: 10848922 - Clin Exp Allergy. 2000 Jul;30(7):994-1000 – reference: 24991450 - Allergy Asthma Immunol Res. 2014 Jul;6(4):276-87 – reference: 24035157 - J Allergy Clin Immunol. 2013 Dec;132(6):1337-47 – reference: 20673359 - BMC Microbiol. 2010 Jul 30;10:206 – reference: 23197906 - Ann Dermatol. 2012 Nov;24(4):413-9 |
SSID | ssj0008661 |
Score | 2.314728 |
Snippet | Background/Objectives
The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin... The use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is... |
SourceID | pubmedcentral proquest pubmed crossref wiley istex |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 165 |
SubjectTerms | Child, Preschool Dermatitis, Atopic - drug therapy Emollients - administration & dosage Humans Infant Original Skin - drug effects Skin - microbiology Staphylococcus aureus - drug effects Staphylococcus epidermidis - drug effects |
Title | Effects of a New Emollient-Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis |
URI | https://api.istex.fr/ark:/67375/WNG-C1JG1VCM-T/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpde.12786 https://www.ncbi.nlm.nih.gov/pubmed/27001317 https://www.proquest.com/docview/1775381174 https://pubmed.ncbi.nlm.nih.gov/PMC5071726 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qBfHF-llTtawi4kuOS7LZTelTe71rKVwpctU-CCH7ETx6Jsd9gPjkQ_-A_o39S5zZfNjTCuJbILNJdjOz85vd2d8AvCW3g46fGC6l8rmUmZ8YHfk6UgkPQyVjS-sdwxNxdMaPz-PzNdhtzsJU_BDtghtZhpuvycAzNb9h5FNjO0GIb8L5l3K1CBB9-EUdlQjHlYoaTIS7XNSsQpTF07Zc8UV3aVi_3QY0_8yXvIljnSMabMDnpgtV_slFZ7lQHf39N3bH_-zjQ3hQA1S2V2nUI1izxWO4N6y34J_AZcV3PGdlzjKGcyTrfyVib_zo6x9X--gUDRs12eusLBiV92JDyvvLJ6hvbJ-SKbVlWWHwekYV89gAvStpCEPRXn28nNESMTacGLa3KKdjzQ5sha_H86dwNuiPekd-XcrB1zzGP6BEzA3GbpkRseIij8ROYjAi1qIbSYyiBFUYj5QIEq1D25VaJTkONyL_PDBc5dEzWC_Kwj4HJro62zEI2wyxFVqTyFxhpJ0bhe44i4UH75ufmuqa55zKbUzSJt7BUU3dqHrwphWdVuQetwm9c5rRSmSzC8qGk3H66eQw7QXHh8HH3jAdefC6UZ0UbZQ2XrLClst5GkgMCulEL_dgs1Kl9mlu4x9BnAdyRclaAeL_Xr1TjL84HnCC8jKkDjsd-nsX0tODvrvY-nfRF3AfsaGo0u1ewvpitrSvEH8t1DbcCfnptjO3n66iLS0 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEB6VVoK-cB_mXBBCvDiKr11X4qVNk4ZSRwil0BdkeQ-rUYMd5ZAQTzzwA_iN_BJm1gcNFAnxZinjJLv-xvPN7uw3AM8p7GDgJ4VLId1QiMyNtQpcFcg49H0pIkPrHcmID4_Dw5PoZANeNWdhKn2IdsGNPMO-r8nBaUH6nJfPtOl4Pv7UJdiijt42oXr3Szwq5lYtFTFMkrshr3WFqI6nvXUtGm3RxH6-iGr-WTF5nsnaUDS4Bh-bQVQVKGed1VJ21Jff9B3_d5TX4WrNUdluBaobsGGKm3A5qXfhb8G3SvJ4wcqcZQxfk6z_ibS98V__-Pp9D-OiZuOmgJ2VBaMOXyyh0r98ipBje1RPqQzLCo3Xc2qaxwYYYAkkDE179QlzRqvEeONUs91lOZsotm8qij1Z3IbjQX_cG7p1NwdXhRE-AsmjUGP6lmkeyZDnAd-JNSbFincDgYkUpybjgeRerJRvukLJOMf5RvKfezqUeXAHNouyMPeA8a7KdjQyN02ChUbHIpeYbOdaYkTOIu7Ay-appqqWOqeOG9O0SXlwVlM7qw48a01nlb7HRUYvLDRai2x-RgVxIko_jA7Snnd44L3vJenYgacNdlJ0U9p7yQpTrhapJzAvpEO9oQN3Kyy132b3_pHHOSDWUNYakAT4-ifF5NRKgRObFz4N2ILo70NI3-737cX9fzd9AleG4-QoPXo9evMAtpEq8qr67iFsLucr8wjp2FI-tl73E0ECMHE |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbhNBEC2FRIq4sC_D2iCEuNjybN0TcUq8JARsRciBHJBa08soVpwZy4uEOHHgA_hGvoSqnoUYgoS4jeQa293zaupVd_UrgBcUdjDwk8KlUK1IiLSVGB22dKiSKAiUiC2tdwxH_OA4OjyJTzbgdX0WptSHaBbcyDPc-5ocfGayC04-M7btB_hLV2Ar4p2EIN17_0s7KuFOLBUhTIq7Ea9khaiMp7l1LRht0bx-voxp_lkweZHIukg0uA6f6jGUBShn7dVStfWX3-Qd_3OQN-BaxVDZbgmpm7Bh81uwPaz24G_Dt1LweMGKjKUMX5Ksf07K3vinf3z9vodR0bBxXb7OipxRfy82pMK_bIqAY3tUTaktS3OD13NqmccGGF4JIgxNu9X5ckZrxHjj1LDdZTGbaNazJcGeLO7A8aA_7h60ql4OLR3F-AQUjyODyVtqeKwinoV8JzGYEmveCQWmUZxajIeK-4nWge0IrZIMpxupf-abSGXhXdjMi9zeB8Y7Ot0xyNsMyRVak4hMYaqdGYXxOI25B6_qhyp1JXRO_Tamsk54cFalm1UPnjems1Ld4zKjlw4ZjUU6P6NyOBHLj6N92fUP9_0P3aEce_Csho5EJ6WdlzS3xWohfYFZIR3pjTy4V0Kp-Ta3848szgOxBrLGgATA1z_JJ6dOCJy4vAhowA5Dfx-CPOr13cWDfzd9CttHvYF892b09iFcRZ7Iy9K7R7C5nK_sY-RiS_XE-dxPsiovKQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+a+New+Emollient-Based+Treatment+on+Skin+Microflora+Balance+and+Barrier+Function+in+Children+with+Mild+Atopic+Dermatitis&rft.jtitle=Pediatric+dermatology&rft.au=Bianchi%2C+Pascale&rft.au=Theunis%2C+Jennifer&rft.au=Casas%2C+Christiane&rft.au=Villeneuve%2C+Cecile&rft.date=2016-03-01&rft.eissn=1525-1470&rft.volume=33&rft.issue=2&rft.spage=165&rft_id=info:doi/10.1111%2Fpde.12786&rft_id=info%3Apmid%2F27001317&rft.externalDocID=27001317 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0736-8046&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0736-8046&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0736-8046&client=summon |